Statistics from Altmetric.com
We read with interest the original article by Tillack et al who reported the characteristics of psoriasiform skin lesions induced by antitumour necrosis factor (anti-TNF)-α in patients with IBD.1 The authors show by immunohistochemical analysis that cutaneous lesions are characterised by interferon (IFN)α expression, infiltrates of interleukin (IL)-17A/IL-22-secreting T helper (Th)17 cells and IFNγ-secreting Th1 cells. They also demonstrate that therapy with ustekinumab, an anti-IL-12/IL-23 antibody, is highly effective in treating anti-TNF-α antibody-induced psoriasis and psoriasiform lesions.
Our group is interested in the pathogenesis of psoriasiform lesions induced by anti-TNF-α antibodies in IBD patients. We found an interesting case of an 18-year-old man diagnosed with ileo-colonic Crohn's disease in 2003. In June 2009, the patient presented with back pain and impaired spinal mobility and was diagnosed with ankylosing spondylitis by lumbar MRI. Since symptoms did not improve with steroids and physiotherapy, he switched to adalimumab (40 mg every other week following 160/80 mg induction …